2021 Update Bulletin on Multiple Sclerosis – Ocrevus Has Been Approved by the European Commission – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Multiple Sclerosis: Update Bulletin” newsletter has been added to ResearchAndMarkets.com’s offering.
This report presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market.
Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab) has been approved by the European Commission as a treatment for RRMS and PPMS; Mylan announcing the UK launch of Brabio (glatiramer acetate injection; 40 mg/ml), a generic version of Copaxone; as well as Merck KGaA’s potential FDA resubmission for Mavenclad (cladribine tablets) as a therapy for relapsing forms of MS.
Business Questions:
- How is Ocrevus expected to be prescribed once launched?
- Which agents are anticipated to lose market share as a result of Ocrevus’ launch?
- How do KOLs view Brabio and how successful is it likely to be?
- How do KOLs view Mavenclad, and how successful has the European launch been?
- How is Mavenclad currently prescribed?
For more information about this newsletter visit https://www.researchandmarkets.com/r/tmzkvv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
